News | August 11, 2025
Emcure Pharmaceuticals reports Q1 FY26 consolidated PAT higher at Rs. 206.95 Cr
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
Emcure Pharmaceuticals has reported total income of Rs. 2,104.23 crores during the period ended June 30, 2025
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Prucalopride is prescribed for chronic idiopathic constipation
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
This is the group’s first NoC approval in Canada
Vasograin Plus represents a major advancement in the treatment of migraine
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Athena is also exploring the use of this technology for expanded carrier screening
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Subscribe To Our Newsletter & Stay Updated
